"Cytochrome P-450 CYP2D6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
| Descriptor ID |
D019389
|
| MeSH Number(s) |
D08.244.453.005.600 D08.244.453.491.372 D08.811.682.690.708.170.010.600 D08.811.682.690.708.170.450.368 D12.776.422.220.453.010.600 D12.776.422.220.453.491.368
|
| Concept/Terms |
Cytochrome P-450 CYP2D6- Cytochrome P-450 CYP2D6
- CYP2D6, Cytochrome P-450
- Cytochrome P 450 CYP2D6
- P-450 CYP2D6, Cytochrome
- Sparteine Monooxygenase
- Monooxygenase, Sparteine
- Cytochrome P450 2D6
- P450 2D6, Cytochrome
- Debrisoquine 4-Monooxygenase
- 4-Monooxygenase, Debrisoquine
- Debrisoquine 4 Monooxygenase
- Imipramine 2-Hydroxylase
- 2-Hydroxylase, Imipramine
- Imipramine 2 Hydroxylase
- CYP2D6
- CYP 2D6
- Debrisoquine 4-Hydroxylase
- 4-Hydroxylase, Debrisoquine
- Debrisoquine 4 Hydroxylase
- Debrisoquine Hydroxylase
- Hydroxylase, Debrisoquine
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6" by people in this website by year, and whether "Cytochrome P-450 CYP2D6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2D6" by people in Profiles.
-
Huestis MA, Smith WB, Leonowens C, Blanchard R, Viaccoz A, Spargo E, Miner NB, Yazar-Klosinski B. MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis. CPT Pharmacometrics Syst Pharmacol. 2025 02; 14(2):376-388.
-
Raymond M, Critchlow E, Rice SM, Wodoslawsky S, Berger SI, Hegde M, Empey PE, Al-Kouatly HB. Fetal pharmacogenomics: A promising addition to complex neonatal care. Mol Genet Metab. 2022 Sep-Oct; 137(1-2):140-145.
-
Kumar A, Kearney A. The use of pharmacogenetic testing in psychiatry. J Am Assoc Nurse Pract. 2021 Nov 10; 33(11):849-851.
-
Ouerhani S, Marrakchi R, Bouhaha R, Ben Slama MR, Sfaxi M, Ayed M, Chebil M, El Gaaied AB. The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients. Bull Cancer. 2008 Feb; 95(2):E1-4.
-
Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr; 33(4):500-7.